Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Increases By 5.6%

INmune Bio, Inc. (NASDAQ:INMB) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 2,830,000 shares, a growth of 5.6% from the September 30th total of 2,680,000 shares. Based on an average daily volume of 225,300 shares, the days-to-cover ratio is presently 12.6 days.

INmune Bio Stock Performance

Shares of INMB opened at $5.95 on Thursday. The company has a market capitalization of $117.58 million, a P/E ratio of -2.89 and a beta of 1.85. INmune Bio has a one year low of $4.78 and a one year high of $14.74. The stock has a 50-day moving average price of $5.68 and a 200 day moving average price of $7.84.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%. As a group, equities research analysts forecast that INmune Bio will post -2.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on INMB shares. Alliance Global Partners started coverage on INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 target price for the company. Scotiabank started coverage on INmune Bio in a research note on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 target price for the company. Finally, Raymond James started coverage on INmune Bio in a research note on Friday, September 27th. They issued an “outperform” rating and a $18.00 target price for the company.

Insider Activity at INmune Bio

In other INmune Bio news, CFO David J. Moss bought 7,690 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average cost of $6.38 per share, for a total transaction of $49,062.20. Following the completion of the purchase, the chief financial officer now owns 1,275,869 shares of the company’s stock, valued at $8,140,044.22. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO David J. Moss purchased 10,000 shares of the company’s stock in a transaction on Monday, September 30th. The stock was bought at an average cost of $5.29 per share, for a total transaction of $52,900.00. Following the completion of the purchase, the chief financial officer now directly owns 1,285,869 shares of the company’s stock, valued at $6,802,247.01. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO David J. Moss purchased 7,690 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were purchased at an average price of $6.38 per share, with a total value of $49,062.20. Following the completion of the purchase, the chief financial officer now directly owns 1,275,869 shares of the company’s stock, valued at $8,140,044.22. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 33,070 shares of company stock worth $200,087. 35.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Fermata Advisors LLC boosted its holdings in INmune Bio by 8.5% in the second quarter. Fermata Advisors LLC now owns 34,140 shares of the company’s stock valued at $301,000 after purchasing an additional 2,689 shares during the last quarter. CVI Holdings LLC purchased a new position in INmune Bio in the second quarter valued at about $5,260,000. Rhumbline Advisers purchased a new position in INmune Bio in the second quarter valued at about $121,000. Bank of New York Mellon Corp boosted its holdings in INmune Bio by 124.6% in the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after purchasing an additional 32,511 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in INmune Bio by 332.1% in the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after purchasing an additional 89,091 shares during the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.